Tags : Provide

AstraZeneca Collaborates with Gendius to Provide Diabetes Management Support for

Shots: The collaboration is built on Gendius’ diabetes management platform, Intellin, which has 200,000+ downloads worldwide. With the partnership, AstraZeneca allows HCPs across the Gulf region to use Gendius’ Intellin to augment diabetes management for reducing the incidence of complications The partnership is being implemented within the framework of AstraZeneca’s Emerging Markets Health Innovation Hubs […]Read More

Denali and Sanofi Provide Update on its RIPK1 Program

Shots: Denali reported the results of P-Ib studies of DNL747 in AD and ALS and provides an update on its broad RIPK1 program including DNL788 and DNL758. The P-Ib studies has met its safety endpoints in patients with ALS and AD, further dose escalation to achieve higher levels of target inhibition may be limited by […]Read More

NeoGenomics Collaborates with Bayer to Provide NTRK Testing for Patients

Shots: Shots: The companies enter into a collaboration to test RNA-based NTRK gene fusions in colorectal and thyroid cancer patients, enrolled in the Sponsored Testing Program The sponsored Test4TRK program will provide RNA-based NTRK gene fusions test along with Pan-TrK IHC test in mCRC patients (high MSI-H status/deficient DNA MMR) as wells as in patients […]Read More

Pfizer and BioNTech Provide Updates on its Collaboration for Global

Shots: BioNTech to receive $185M up front, including $72M cash & $113M equity investment, up to $563M as milestone making a total deal value $748M. The companies will equally share the development cost while Pfizer will fund 100% of development cost at the initial level and BioNTech will repay Pfizer its 50% share during the […]Read More

Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar

Revance to get $25M upfront, milestone payments upon achievement of additional clinical, regulatory and sales targets, plus sales royalties in all relevant markets and will be finalized till Apr 30, 2020 In Feb 2018, Revance and Mylan signed global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA) […]Read More

Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar

Revance to get $25M upfront, milestone payments upon achievement of additional clinical, regulatory and sales targets, plus sales royalties in all relevant markets and will be finalized till Apr 30, 2020 In Feb 2018, Revance and Mylan signed global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA) […]Read More

Abbott Collaborates with Omada Health to Provide Integrated Digital Health

Shots: The collaboration integrates Abbott’s FreeStyle Libre system, a CGM technology, with Omada Health’s digital care program focusing to create a new paradigm for patients with T2D The integrated solution with Omada expand access to FreeStyle Libre and provide real-time glucose data and actionable information for patients to better manage their diabetes and guide personalized […]Read More